NeoGenomics Inc (NEO)

[altarboy4]

Or did I miss something? All this crap gets so confusing. I just hope we don't get screwed. This stock is doing extremely well and the company's financials look outstanding. You mentioned that PR. Is that information good for a positive PR?

[altarboy4]

Cashprofitsss does this mean we're going to get screwed?? Why can't they do a F/S and not dilution?

[cashprofitsss]

These guys are thrilled to have a contract with Neogenomics


Ikonisys Awarded Platform Contract by NeoGenomics Laboratories for Automated Cell-Based Diagnosis

Tuesday August 1, 7:48 am ET
Leading developer of automated cell-based diagnostic products adds major new customer

NEW HAVEN, Conn., Aug. 1 /PRNewswire/ -- Ikonisys, Inc. announced today that it is has been awarded a multi-year, multi-unit contract by NeoGenomics Laboratories to procure and deploy the Ikoniscope(TM)/IkoniLAN(TM) robotic microscopy platform.
"We're very pleased to broaden our relationship with NeoGenomics," said Dr. Petros Tsipouras, Chairman and CEO of Ikonisys, "and we look forward to working with their team to engage the capabilities of our world-class microscopy platform for their cancer diagnostic needs."

Mr. Robert Gasparini, President and Chief Scientific Officer of NeoGenomics Laboratories, stated, "The Ikonisys robotic microscope truly represents the next generation of FISH (fluorescence in-situ hybridization) analysis automation by allowing previously unreachable analytical sensitivities. We are excited to be the first cancer diagnostic company to fully integrate the Ikonisys robotic microscopy platform into our service."

Ikonisys has developed the Ikoniscope(TM)/IkoniLAN(TM), a robotic microscopy system for fully automated, high-throughput signal detection and analysis. In February 2006 the Company announced that the Food and Drug Administration (FDA) cleared for marketing in the United States its automated cell-locating device, the Ikoniscope(TM) fastFISH(TM) amnio test system. The Company is developing several products and applications for cancer and prenatal diagnosis/screening based on the utilization of its robotic microscopy system.

About Ikonisys

Ikonisys, a global leader in the advancement of cell-based diagnostic products, has developed a platform of robotic microscopy. Based on its proprietary technology, Ikonisys aims to expand this novel field with products in the genetic disease, oncology, and fertility areas. Additional information about Ikonisys can be found at http://www.ikonisys.com.

About NeoGenomics Laboratories

NeoGenomics Laboratories is a high-complexity CLIA-certified clinical laboratory that offers cancer genetic diagnostic testing services including cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry and molecular genetic testing. NeoGenomics is headquartered in Fort Myers, FL with a second operation in Nashville, TN and services the needs of oncologists, pathologists, urologists, hospitals and other reference laboratories not offering genetic testing throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.org.


Contact:

Petros Tsipouras, MD
Chairman and CEO
Ikonisys, Inc.
Phone Number: 203-776-0791
Email: [e-mail]

[cashprofitsss]

Yes, that .ob on the end of the NGNM stock symbol keeps the majority of serious investors away from investing in this well-run company. (The saying is ".ob" stands for ostensibly broke.) I would expect them to move the stock over to the AMEX in time...I believe the fees are less than NASDAQ, though putting it on the NASDAQ would be the best move. That would be a good question to ask at the next Quarterly conference. If and when or are they even contemplating it?

[altarboy4]

This damn thing will be on NASDAQ before we know it. And I hope some forward splits coming down the pike to make up for that God-awful 100/1 RS ahwile back. Keeping fingers crossed.

[cashprofitsss]

Company update 2Q '06

http://www.americanmicrocaps.com/ngnm/NGNM_Q2_Update.pdf

[cashprofitsss]

1,800,000 secondary shares to be sold. That's less than the 5M that were to be sold with the previous 10M filing. I would imagine they have buyers already lined up for those shares. Management explained that the previous filing was only an updated filing and do not have plans to use the SEDA -unless an opportunity were to arise.

http://www.sec.gov/Archives/edgar/data/1077183/000107087606000093/neo072806sb2.htm

OK guys so where is the PR?

[cashprofitsss]

10,000,000 shares being sold

gonna see some dilution...surprised that the company isn't being forthright about this -no PR has been issued yet.

http://www.sec.gov/Archives/edgar/data/1077183/000110801706000502/ngposam.htm

[altarboy4]

Cashprofitsss thanks for the info. The problem here is that I only have 104 shares after that horrible R/S ahwile back. Can't buy anymore at this point. That is why I was hoping for a F/S.

[cashprofitsss]

I don't believe we will see any splits -not necessary yet. We might see more dilution with more new shares being offered to private investors...which is what next weeks investment conference would be about. With additional cash Neogenomics could expand even quicker...so it's a good thing. There is a an analyst target for $1.50 to $1.75 for next year...nothing about $4. That price is possible but it is 2 to 4 years out in my opinion. Either Quest Diagnostics (DGX) or Laboratory Corp (LH) will probably buy Neogenomics out at that point. Keep holding on to those shares...they are going to be valuable.

Here's an update to the main report, if you haven't read it yet. http://www.americanmicrocaps.com/ngnm/NGNM_Q1_Update.pdf

Also they have a link to level II bid & ask prices on NGNM...investors have been upping their asking prices lately.

http://www.americanmicrocaps.com/ngnm/

Good Luck

[altarboy4]

The SP/volume does appear to be heading north. Does anyone know anything about some sort of target share price of $4? Also if this stock really starts to roar I hope they do a forward split so we can recover some of our shares from that devastating RS awhile back.

[cashprofitsss]

Arch Investment Conference Thursday, June 15, 2006 in New York for Small and Micro-cap Companies

Arch Investment Conferences 2006
NEW YORK--(BUSINESS WIRE)--June 8, 2006--Arch Investment Conferences, Inc. is proud to announce its 2006 conference series continues as a dynamic set of small- and micro-cap companies present to the investment community on Thursday, June 15 in New York at the Hotel Plaza Athenee. Featured guest panelists include Josh Levine of ChangeWave.com and Peter Leeds of PeterLeeds.com.

Presenting companies include:

Baldwin Technology Co. Inc. (AMEX:BLD)
Synergetics USA (NASDAQ:SURG)
NeoGenomics Inc. (OTCBB:NGNM)
China Digital Communication Group (OTCBB:CHID)
Acrongenomics, Inc. (OTCBB: AGNM)

The Hotel Plaza Athenee is located at 37 East 64th Street (at Madison Ave.), New York, N.Y. 10021.

Breakfast and registration begin at 8:00 a.m.

The entire event will be webcast and available for 90 days through Vcall at http://www.informedinvestors.com/VC/ClientPage.asp?ID=45356 and at www.investrend.com.

Attendance at Arch conferences is open only to qualified investment professionals, and by invitation only. We encourage institutional investors as well as buy-side money managers, small/micro cap analysts, and portfolio managers to inquire about attending Arch conferences as our guests. For more information, or to request an invitation, please contact German de la Roche at [e-mail] or call 866-707-7920.

This event is sponsored by: Tobin Smith and ChangeWave, Charles Payne and Wall Street Strategies, PeterLeeds.com, Wall Street Calendar, Investrend Research, Business Wire, and ArchInsight.com

About Arch Investment Conferences, Inc.

Arch Investment Conferences was founded in 2005 by German de la Roche. Arch's audience has grown substantially and more than 1,600 investors, primarily institutional, have attended or been part of the conference and webcasts. With eight conferences in 2006 in New York City and three West Coast conferences beginning in September 2006, Arch plans to continue delivering on its promise to be a bridge to the companies of tomorrow. For more information, visit http://www.archconferences.com.

Companies interested in presenting please contact German de la Roche.

http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20060608005....

[cashprofitsss]

NeoGenomics Expands Investor Relations Program
Cancer Genetic Testing Company Selects Hawk Associates for Additional Services
Last Update: 2:00 PM ET May 25, 2006


FORT MYERS, Fla., May 25, 2006 /PRNewswire-FirstCall via COMTEX/ -- NeoGenomics, Inc. (NGNMneogenomics inc com new
News , chart, profile, more

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
NGNM ) a high-complexity CLIA-certified clinical laboratory that offers cancer genetic diagnostic testing services nationwide, announced today that it has increased the scope of its investor relations program with Hawk Associates. Beginning today, NeoGenomics will be featured for investor awareness and information on the Hawk Associates website, http://www.hawkassociates.com , in addition to the American Microcap Institute website, http://www.americanmicrocaps.com .
Hawk Associates will provide additional services for the company, including a virtual investor relations kit, e-mail alerts about news from the company, regular company profile updates, assistance with quarterly conference calls, and press release support. Hawk will also handle investor queries for the company.
Frank Hawkins, CEO of Hawk Associates, said, "We are pleased that NeoGenomics has expanded its investor relations program. The company recently reported its first profitable quarterly results and has completed an accretive acquisition of a lab centrally located in Nashville, TN. We look forward to working closely with this energetic young company to help tell its story to investors."
Robert Gasparini, president of NeoGenomics, said, "We have grown to the point where it is important to have a full-service investor relations firm available to help us communicate effectively with our shareholders while the management team concentrates on executing our strategy for growth. Hawk Associates has done an excellent job in articulating the investment thesis for NeoGenomics through their 37 page in-depth equity research report, which they published through their American Microcap Institute subsidiary. We plan to build upon this effort through the state-of-the-art Hawk website that also offers a virtual investor kit for 24/7 access by investors. We encourage investors to take advantage of Hawk's e-mail alert system."
Information for investors, including a profile of NeoGenomics and the subscription form for free NeoGenomics e-mail alert notifications can be obtained by visiting http://www.hawkassociates.com or http://www.americanmicrocaps.com . Interested parties can also access an in- depth equity research report from the American Microcap Institute at http://www.americanmicrocapinstitute.com/ngnm .
About NeoGenomics, Inc.
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that offers cancer genetic diagnostic testing services including cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry and molecular genetic testing. NeoGenomics is headquartered in Fort Myers, Fla., and services the needs of oncologists, pathologists, urologists, hospitals and other reference laboratories not offering genetic testing throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.org .
An online investor kit including press releases, current price quotes, stock charts and other valuable information for investors may be found at http://www.hawkassociates.com and http://www.americanmicrocaps.com. For investor relations questions regarding NeoGenomics, contact Frank Hawkins or Julie Marshall, Hawk Associates, at [phone], e-mail: [e-mail] .
About Hawk Associates, Inc.
Hawk Associates, Inc. is a full-service national investor relations and financial media relations consulting firm serving clients nationwide and in Canada. For more information about Hawk Associates, visit http://www.hawkassociates.com or contact Frank Hawkins or Julie Marshall at [phone], email: [e-mail] .
Forward-Looking Statements
Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements, including, but not limited to, any adverse effect or limitations caused by governmental regulations, the company's ability to attract and retain qualified personnel, to initiate and develop client relationships, to gain market acceptance of service offerings, as well as other risks described from time to time in the company's filings with the Securities and Exchange Commission. Although the company has used its best efforts to be accurate in making those forward-looking statements, there can be no assurance that the assumptions made by management will materialize. In addition, the information set forth in the company's Form 10-KSB for the fiscal year ended December 31, 2005 describe certain additional risks and uncertainties that could cause actual results to vary materially from the future results covered in such forward-looking statements. The company undertakes no obligation to publicly revise or update the forward-looking statements to reflect new information, subsequent events or otherwise.
SOURCE NeoGenomics, Inc.
Steven C. Jones, Director of Investor Relations, NeoGenomics, [phone], or [e-mail]; or Frank N. Hawkins or Julie Marshall, both of Hawk Associates, Inc., [phone], or [e-mail], for NeoGenomics http://www.prnewswire.com Copyright (C) 2006 PR Newswire. All rights reserved.

[cashprofitsss]

Nashville genetics lab acquired by Florida company

Nashville Business Journal
2:40 PM CDT Tuesday
The Center for Cytogenetics, a lab that performs genetic testing for Nashville-area hospitals, has been acquired by a Florida laboratory company for undisclosed terms.

NeoGenomics (OTCBB: NGNM), based in Fort Myers, Fla., announced the acquisition Tuesday along with its first quarter results. The company offers genetic and molecular testing to determine predisposition to certain diseases.

Cytogenetics, which is located in Baptist Medical Plaza in Nashville, was founded in 2002 by Andy Allen, a former laboratory supervisor for Genetic Associates.

"We do chromosome analysis for cancer detection," says Allen, adding that the acquisition means little change for the Nashville lab. "We'll remain in Nashville and be part of a Florida laboratory."

In its earnings release, NeoGenomics officials noted that the acquisition gives the company additional capacity and a site outside of Southwest Florida, which will mitigate the risk of seasonal weather that can disrupt business.

"The opening of our company's second laboratory location ... provides for geographic diversity, additional capacity and is central to our hurricane disaster plan," said Robert Gasparini, president and chief scientific officer.

In its first quarter ended March 31, the company reached profitability, posting earnings of $106,000 compared to a loss of $215,000 in the first quarter last year. Revenues increased from $230,000 to $1.3 million.

http://www.bizjournals.com/nashville/stories/2006/05/08/daily9.html

[cashprofitsss]

Another blowout quarter
plus an acquisition and
their first webcast coming up
on Thursday, May 11th

NeoGenomics, Inc. Announces Quarterly Profitability and Financial Results for First Quarter of FY 2006
Tuesday May 9, 7:00 am ET
Company Also Announces Opening of Second Laboratory in Nashville, TN


FORT MYERS, Fla., May 9 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM - News) announced today quarterly profitability and its financial results for the first quarter of 2006.
Significant accomplishments during the first quarter included the following:


-- 484% year-over-year increase in revenues in Q1 '06 vs. Q1 '05;
-- 79% sequential increase in revenues in Q1 '06 vs. Q4 '05;
-- Average revenue/test increased 5.1% to $504.43 in Q1 '06 from $478.58
in Q4 '05;
-- 37% of cases ordered more than one test per case in Q1 '06 (64%
excluding cases such as UroVysion and PathVysion where only one test is
normally ordered);
-- 120% increase in breast, bladder and cervical FISH testing in Q1 '06
vs. Q4 '05; and
-- Gross margin increase to 57% in Q1 '06, compared to 36% in Q4 '05.

President and Chief Scientific Officer Robert Gasparini said, "I am delighted with the progress we continue to make and am pleased to report that the Company achieved the all-important milestone of becoming net income profitable for the first quarter of 2006. We believe that we have turned the corner to sustained profitability while at the same time scaling our business for substantial growth. During the quarter, we were successful in closing several strategic relationships with large customers, which we believe will continue to fuel our growth throughout 2006 and beyond. In addition, our relatively new testing services for breast, bladder and cervical cancer continue to be well received by the market."

The Company also announced that on April 18, 2006 it completed the purchase and merger of The Center for Cytogenetics, a private genetics testing company located in Nashville, TN, into NeoGenomics, Inc. The merger is of strategic importance and results in the Company acquiring additional capacity and a second site to mitigate the risk of weather-related phenomena common to Southwest Florida. Terms of the merger were not disclosed.

Gasparini said, "The opening of our Company's second laboratory location in Nashville, TN, provides for geographic diversity, additional capacity and is central to our hurricane disaster plan. This facility should allow us to scale more rapidly to meet increasing customer demand. We remain actively engaged in discussions and continue to seek acquisitions which will allow us to further increase our capacity and ramp-up our capabilities."

Acting Principal Financial Officer Steven Jones said, "During the first quarter of 2006, we experienced terrific growth both on a year-over-year basis from Q1 '05 and a sequential basis from Q4 '05. On a year-over-year basis, the Company increased revenues by approximately 484% to $1,344,000 in Q1 '06 from $230,000 in Q1 '05, largely as a result of a greater number of tests being performed for our customers. At the same time, our requisitions increased 431% to 1,948 in Q1 '06 from 367 requisitions in Q1 '05, and our tests increased 470% to 2,664 in Q1 '06 from 467 during Q1 '05. During the first quarter average revenue per requisition increased approximately 10% to $689.84, versus $627.23 during the first quarter of 2005."

"Perhaps most significant, however, was our sequential revenue growth and increases in gross margins from the fourth quarter of 2005. On a sequential basis, we increased revenues by 79% from the fourth quarter of 2005, and our gross margin increased to 57% of revenue from 36% in the fourth quarter of 2005. This increase was primarily driven by the achievement of greater economies of scale as a result of increased testing volumes, a realignment of our pricing policies to be more in line with our overall mix of business, and an aggressive cost containment program begun in the fourth quarter of 2005. When combined, these factors allowed us to achieve significant increases in productivity and decreases in our average cost per test. Although we continue to seek ways to reduce these costs even further, we expect that the integration of our Nashville operations will have some negative impact on our gross margin over the coming quarters. We believe that our long-term margins will eventually settle in the 50-55% range."

"General and administrative expenses also increased in the first quarter by approximately 133% to $591,000 from $254,000 in the first quarter of FY 2005. This increase was largely a result of the increased expenses associated with our management team, which was recruited in the later half of 2005 to position the Company during FY 2006, as well as increased commissions cost related to increased sales."

"During the first quarter of 2006, EBITDA was approximately $225,000, which is an increase of $386,000 from the negative EBITDA of approximately $161,000 in the first quarter of 2005. A reconciliation of the EBITDA calculation to GAAP net income (loss) is contained at the back of this press release. Our net income of approximately $106,000 for the first quarter of FY 2006 increased by $321,000, versus a net loss of $215,000 during the first quarter of 2005. This resulted in earnings per basic share and earnings per diluted share of approximately $0.004."

"At the present time we reiterate our previous guidance for FY 2006 and FY 2007, which we made in our press release of March 14, 2006. Given our current rate of growth, our future performance is exceptionally difficult to predict with any accuracy (especially our FY 2007 guidance). However, based on the current trends, we do not believe any adjustments to this guidance are necessary at this time. Of course, we reserve the right to adjust this guidance at any time based on the ongoing execution of our business plan, and by no means should these estimates be construed as a guarantee of future performance," Jones said.

The Company has scheduled a web-cast and conference call to discuss these results on Thursday, May 11, 2006 at 11:00 AM ET. Interested investors should dial 1-877-407-0778 (domestic) and 1-201-689-8565 (international) at least five minutes prior to the call. A replay of the conference call will be available for two weeks and can be accessed by dialing 1-877-660-6853 (domestic) and 1-201-612-7415 (international). The playback account number will be 286 and the playback pin number is 202503. The webcast may be accessed under the Investor Relations section of the NeoGenomics website at http://www.neogenomics.org. An archive of the webcast will be available until 11:00 a.m. ET on August 12, 2006.

http://biz.yahoo.com/prnews/060509/nytu096.html?.v=47

[cashprofitsss]

American Microcap Institute Initiates Research Coverage of NeoGenomics

Monday April 3, 3:46 pm ET

Medical Laboratory Company Specializes in Genetic Testing for Cancer

KEY LARGO, Fla., April 3 /PRNewswire-FirstCall/ -- The American Microcap Institute (AMI), the leading online resource for microcap investors and a division of Hawk Associates Inc., announced today that it has initiated coverage of NeoGenomics, Inc. (OTC Bulletin Board: NGNM - News) with a long-term accumulate recommendation. NeoGenomics is an independent medical laboratory company specializing in genetic testing for cancer. The analyst report can be accessed from the AMI website, http://www.americanmicrocaps.com .
The report, written by Senior Analyst Cale Smith, provides an overview of NeoGenomics, the range of testing services it offers and the favorable economics of genetic testing. The genetic testing market and NeoGenomics' business strategy are detailed in the report, which provides a complete analysis of the company's financial position and the current investment opportunity.

Hawk Associates CEO Frank Hawkins said, "This is the first analyst report the American Microcap Institute has produced. It is an excellent evaluation of a rapidly emerging company in an important and growing industry. We believe this report provides a critical means of communicating the company's value to the market. With the vast majority of microcap stocks overlooked by Wall Street, we feel our research reports can help promising young companies like NeoGenomics receive the attention they deserve from sophisticated and serious investors. We invite all investors to download this report, which is available free of charge at the American Microcap Institute."

About NeoGenomics, Inc.

NeoGenomics, Inc. is a CLIA-certified medical laboratory specializing in cancer genetic testing services including cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry and molecular tests. The company provides a range of gene-based testing services to oncologists, urologists, pathologists, hospitals and other laboratories from its headquarters in Ft. Myers, Fla. The company differentiates itself through its focus on genetic cancer tests, industry-leading turnaround times and a high level of customer service. NeoGenomics is the only pure-play publicly traded independent genetic testing lab. For additional information about NeoGenomics, visit http://www.neogenomics.org .

An investment profile about NeoGenomics may be found at http://www.americanmicrocaps.com/ngnm/profile.pdf .

To sign up for free e-mail alert notifications about NeoGenomics, Inc., visit http://www.americanmicrocaps.com .

About the American Microcap Institute

The American Microcap Institute (AMI), a subsidiary of Hawk Associates, is dedicated to providing investors with timely and accurate information on companies trading under $5. The AMI website provides investors with a free stock watch list and information about featured microcaps, company headlines, 20-minute-delayed Level II price quotes, e-mail alerts, CEO interviews and research reports. No registration is required to access the site. For more information, visit http://www.americanmicrocaps.com .

About Hawk Associates Inc.

Hawk Associates Inc. is one of America's leading full-service providers of investor relations and media services to microcap and small cap companies. Known for integrity as well as aggressive and dedicated service, Hawk offers Fortune 200 global experience and national award-winning expertise in providing a sustainable and effective interface with Wall Street. Hawk's state-of-the-art websites, leading-edge technology and well-established Wall Street relationships enable the company's clients to reach investors with their stories in a credible and effective manner.

Hawk Associates specializes in helping emerging and unknown companies develop their messages and implement successful IR programs to stand out among the more than 5,000 small and microcap companies on Wall Street. The company has clients throughout the United States, Canada and China.

For more information, contact Frank Hawkins or Julie Marshall at [phone] or visit http://www.hawkassociates.com and http://www.americanmicrocaps.com .




--------------------------------------------------------------------------------
Source: Hawk Associates Inc.

[cashprofitsss]

Level II and Time & Sales

Here's a link to view the Level II and Time & Sales prints

http://www.americanmicrocaps.com/ngnm/

[cashprofitsss]

NeoGenomics Engages Hawk Associates for Investor Relations

Tuesday March 21, 7:00 am ET


FORT MYERS, Fla., March 21 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM - News) today announced that it has engaged Hawk Associates as its investor relations provider.
Robert Gasparini, President of NeoGenomics, said, "Frank Hawkins, Julie Marshall and their highly respected team at Hawk have a strong track record of helping small-cap companies successfully communicate their stories to the financial and investor marketplace. Their proactive and strategic approach together with their state-of-the-art technology and techniques are ideal for NeoGenomics at this time in our development. We have an important and evolving story that is not well known outside of a limited group. We expect the Hawk team to be able to help us effectively communicate our progress and the directions we are headed."

Frank Hawkins, CEO of Hawk Associates, said, "NeoGenomics is at an exciting point in its history. It has demonstrated the power of its business model by expanding into 16 states just over the last year alone. Given the explosion in the use of genetic tests to help diagnose cancer and NeoGenomics' extraordinary customer service and turn-around times, we believe NeoGenomics is extremely well-positioned in this rapidly growing and highly profitable market segment. In addition, as the only publicly traded pure play company focused on genetic and molecular testing services, we believe NeoGenomics offers investors a compelling value proposition. We look forward to keeping Wall Street informed about the company's progress."

Information for investors, including a profile of NeoGenomics and the ability to sign up for free NeoGenomics email alert notifications, may be found at http://www.americanmicrocaps.com .

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that offers cancer genetic diagnostic testing services, including cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry and molecular genetic testing. NeoGenomics is headquartered in Fort Myers, FL and services the needs of oncologists, pathologists, urologists, hospitals, and other reference laboratories not offering genetic testing throughout the United States. For additional information about NeoGenomics, please visit our website at http://www.neogenomics.org . An investment profile about NeoGenomics may be found at http://www.americanmicrocaps.com/ngnm/profile.pdf .

About Hawk Associates, Inc.

Hawk Associates, Inc. is a full-service national investor relations and financial media relations consulting firm serving clients nationwide and in Canada. For more information and a company profile, visit http://www.hawkassociates.com or contact Frank Hawkins or Julie Marshall at [phone] or [e-mail] .

----------------------------------------------------------------

Another smart move!
That's a sharp profile they put out on NGNM

http://www.americanmicrocaps.com/ngnm/profile.pdf

[cashprofitsss]

NeoGenomics hits profit level for first time
Daily News staff

Wednesday, March 15, 2006

Fort Myers-based NeoGenomics Inc. reported Tuesday that it has achieved monthly profitability.

The genetic and molecular diagnostic testing company reached the milestone in February.

In the fourth quarter, the company reported a 453 percent increase in revenues, compared to a year ago. Revenues rose to $750,895, up from $135,820 last year.

Robert Gasparini, company president, said in a statement that he’s pleased with the progress NeoGenomics has made in the past year.

“During 2005, the substantial investments we made in infrastructure, human resources and the sales force began to yield significant dividends,” he said. “Our national expansion strategy has gained considerable momentum, and by December 2005 approximately 60 percent of our revenue was derived from outside the state of Florida.”

For the year, the company saw a 238 percent increase in revenues — from $558,074 to $1,885,324.

Still, the company reported a net income loss of $360,692, or 2 cents a share, in the fourth quarter. That compared to a loss of $309,776, or 1 cent a share, a year ago. For the year, the company had losses of $977,160, or 4 cents a share. That compared to $818,985, or 4 cents a share, a year ago.

NeoGenomics trades under the symbol NGNM on the Over-the-Counter Bulletin Board.

© 2006 Naples Daily News and NDN Productions. Published in Naples, Florida, USA by the E.W. Scripps Co.

http://www.naplesnews.com/news/2006/mar/15/neogenomics_hits_profit_level_first_time/?print=1

[cashprofitsss]

Finally! the company is out of the red and into the black. It's been a long time in coming. Congratulations to Michael Dent, Steven Jones and -especially- Robert Gasparini and his team. I'm looking forward to the day Neogenomics starts its genetic research projects. The investor relations program is another excellent idea...won't be long till NGNM is off the BB stocks. I can see you moving it to the AMEX or, ideally, the NASDAQ. Gasparini sure makes things happen!

Again, Congratulations,

Greg

[Golden Cross]

NGNM NeoGenomics, Inc. Announces the Achievement of Monthly Profitability, Financial Results for the Fourth Quarter and Full Year of FY 2005, and Analyst Guidance for FY 2006 and FY 2007
PR Newswire - March 14, 2006 7:00 AM (EDT)

FT. MYERS, Fla., March 14, 2006 /PRNewswire-FirstCall via COMTEX/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM) today announced its results for the fourth quarter and full year of fiscal 2005. Significant accomplishments during the fourth quarter and year included the following:

Fourth Quarter 2005 Accomplishments:
* 453% year-over-year increase in revenues in Q4 05 vs. Q4 04
* 34% sequential increase in revenues in Q4 05 vs. Q3 05
* Avg. Revenue/Case increased 12.5% to $685.75 in Q4 05 from $609.31 in
Q3 05
* 44% of cases ordered more than one test per case in Q4 05 vs. 38% of
cases in Q3 05
* Avg. Revenue/Test increased 8.3% to $476.46 in Q4 05 from $440.09 in
Q3 05

Full Year 2005 Accomplishments:
* 238% increase in revenues during FY 2005 vs. FY 2004
* Case volume increased 162% to 2,982 cases in FY 2005 from 1,139 cases
in FY 2004
* Avg. Revenue/Case increased 29.0% to $632.23 in FY 2005 from $489.97 in
FY 2004
* Test volume increased 254% to 4,082 tests in FY 2005 from 1,152 tests
in FY 2004
* 37% of Cases ordered more than one test per case in 2005 vs. 1% of
cases in 2004

Robert Gasparini, the Company's President, stated, "I am delighted with the progress we continue to make, and I am pleased to report that the Company achieved the all important milestone of becoming net income profitable in February of 2006. During 2005, the substantial investments we made in infrastructure, human resources and the sales force began to yield significant dividends. Our national expansion strategy has gained considerable momentum, and by December of 2005 approximately 60% of our revenue was derived from outside of the State of Florida. This is a substantial accomplishment considering that 100% of our revenue was derived from Florida sources at the end of 2004. We now service clients in 16 states and this number continues to grow each quarter. Customers continue to be attracted to our exceptional turn-around times and customer service."

Mr. Gasparini went on to say, "During the fourth quarter, we deliberately chose to slow our top line growth rate a little so that we could further add to our infrastructure. These adjustments have now largely been completed, and we have begun to scale our business quite rapidly during the first quarter of 2006. Our CancerLink(TM) Laboratory Information System (LIS), which we announced during the third quarter of 2005, has proven to be the "killer application" that we hoped it would be and is resulting in substantial increases in our productivity and customer satisfaction. In addition, our new breast, bladder and cervical cancer testing services have been warmly embraced by both new and existing customers."

Mr. Gasparini concluded by saying, "We are planning several new initiatives during 2006 which should help to take our business to the next level. We are in the final stages of our strategic planning on the design and location of a second laboratory facility outside of the State of Florida to provide for geographic diversity and additional capacity. Several locations are under consideration and we plan to make a final determination by the end of the second quarter. In addition, we are currently considering several strategic initiatives with our larger customers to further increase our volumes. Lastly, we are in the process of formalizing an investor relations program, which we believe will help to provide more information to investors about our business. We appreciate the patience our shareholders have displayed while we organize a truly scaleable business."

Steven Jones, the Company's acting Principal Financial Officer and a Director, stated, "During 2005, we began to see considerable economies of scale. Our gross margin increased to 37% of revenue from a deficit position in 2004. In addition, the number of cases in which we performed more than one test increased dramatically to 37% of cases in 2005 versus just 1% of cases in 2004. This increase was driven primarily by our new product offerings and is leading to higher gross margins. Moving forward, we expect our gross margins to continue to increase slowly, and we believe that 45% gross margins are attainable by the end of 2006. Although our general and administrative expenses increased by 104% to $1,447,000 in FY 2005 from $711,000 in FY 2004, we have now largely completed the hiring of our core management team which was the largest driver of this increase. Moving forward, we expect increases in our overhead expenditures to be more in line with industry averages for the rate of revenue growth we achieve. For the year, our net loss increased by approximately 22% to $997,000, or $0.04/share. This was largely a result of the increased general and administrative expenses in FY 2005 associated with preparing our business to be able to continue to scale during FY 2006 and a non-recurring asset impairment charge of $50,000.

Mr. Jones went on to say, "During the fourth quarter of 2005, we increased revenues by approximately 453% to $751,000 from $136,000 during the fourth quarter of 2004, largely as a result of a greater number of tests being performed for our customers. During the fourth quarter average revenue per test increased approximately 8.3% to $476.46 versus $440.09 during the fourth quarter of 2004. General and administrative expenses increased in the fourth quarter by approximately 90% to $501,000 from $263,000 in the fourth quarter of FY 2004. This increase was largely as a result of preparing our business to be able to continue to scale during FY 2006. During the fourth quarter of 2005, we also took a $50,000 asset impairment charge to reduce the carrying value of a mass spectrometer to more accurately reflect our estimate of the current market value of this piece of equipment. Our net loss of $361,000 for the fourth quarter of FY 2005 increased by approximately 16%, or $51,000, versus a net loss of $310,000 during the fourth quarter of 2004, largely as a result of the $50,000 non-recurring asset impairment charge.

Mr. Jones concluded by saying, "Recently we have been asked by several investors and research analysts to provide some guidance for FY 2006 and FY 2007. Given our current rate of growth, this is exceptionally difficult to predict with any accuracy. However, in keeping with our goal of formalizing an investor relations program, we are providing the following guidance for investors. Based on our current rate of growth, we are currently planning on doubling our staff by year-end, which we believe will allow us to triple our test volumes from 4,082 tests in 2005 to approximately 12,000 tests in 2006. Providing we are able to do this, we believe that we can achieve FY 2006 revenues of approximately $5.0 - $6.0 million and net income of approximately $400,000 - $500,000. FY 2007 is even more difficult to predict, however, provided that we can continue to scale our human resource infrastructure, we believe that we can double our test volumes again to approximately 24,000 tests in 2007. If we are able to achieve this level of test volumes in 2007, we believe that we can attain approximately $10.0 - $12.0 million of revenue and approximately $1.0 - $1.2 million of net income. Of course, we reserve the right to adjust this guidance at any time based on the ongoing execution of our business plan, and by no means should these estimates be construed as a guarantee of future performance."

The attached financial results, including a reconciliation of non-cash and non-recurring expenses, should be read in conjunction with the Company's Annual Report on Form 10-KSB, which will be filed with the SEC by March 31, 2006.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that offers cancer genetic diagnostic testing services including cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry and molecular genetic testing. NeoGenomics is headquartered in Fort Myers, FL and services the needs of oncologists, pathologists, urologists, hospitals, and other reference laboratories not offering genetic testing throughout the United States. For additional information about NeoGenomics, please visit our website at www.neogenomics.org.

[cashprofitsss]

Other Message Boards

There's a real active board over at allstocks.com

http://www.allstocks.com/stockmessageboard/ubb/ultimatebb.php/ubb/get_topic/f/2/t/010333/p/5.html

Also another board at thelion.com but not active. One good post. Hope he held in there during the decline.

http://www.thelion.com/bin/forum.cgi?msg=966&tf=otcbb_plays_&cmd=read_next

bought 5K at .40 cents (my disclosure)

Went on a tour of the new facility last year, and again a few weeks ago. Very low salaries for management, they are banking on the stock and company taking off.

They are working with a new biotechnology division at Gulf Coast University (thanks Jeb Bush...) on various new testing and technologies.

They are also working with stem cell research using some sort of marine life, forgot the name with GCU. The university is building a new state of the art 75,000sf. biotechnology building, and neogenomics is right next door, and has a great working relationship with the head of the biotechnology department.

Found this article from 2 years ago: Neogenomics has grown since then.

"To attract more high-tech companies, however, the region needs new research and technology parks; already, a few developers have unveiled plans for such parks. In Lee, Alanda Ltd.’s O. J. Buigas, economic development officials and FGCU are partnering to develop the 100-acre Florida Gulf Coast Technology and Research Park between the university and Southwest Florida International Airport. The goal is to draw large technology and biomedical companies and other businesses, all with a research component. On 20 acres at the center of the park, FGCU will house research efforts as well as its Small Business Development Center and Center for Leadership and Innovation. NeoGenomics, a genetic research lab, is the only non-university tenant to be announced so far."

Very impressed with the management. Will buy more if it dips. Check out the press release and profile. They are the first successful biotech company in the new biotech park.

good luck,
yarddog

[cashprofitsss]

NeoGenomics, Inc. Announces New Equity Financing and Planned Amendments to Its Credit Facility
Wednesday January 25, 7:00 am ET

FT. MYERS, Fla., Jan. 25 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM.OB - News) today announced that it had reached agreements for up to $600,000 of new equity financing for the Company as well as planned amendments to its credit facility. As part of these agreements, a new investor to the Company has purchased 2.0 million restricted shares of the Company's common stock at a purchase price $0.20/share, which has resulted in $400,000 of new equity capital coming into the Company. This investor was also granted a warrant to purchase 900,000 shares of common stock at an exercise price of $0.26/share. As part of the equity agreements and planned credit facility amendment, the Company also granted the right to purchase an additional $200,000 of equity under the same terms by April 30, 2006 to Aspen Select Healthcare, LP ("Aspen") the Company's largest shareholder and creditor, provided that if Aspen elects not to exercise such rights, then the Company may make such shares available for purchase to the new investor.
Under the terms of the planned credit facility amendment, the Company and Aspen have agreed to extend the maturity date until September 30, 2007 and increase the availability of such credit facility by up to $200,000 in certain circumstances. In addition to other items, the planned amendment will provide the company with the ability to access up to $500,000 in secured vendor financing and/or lease arrangements.

Robert Gasparini, the Company's President, stated, "I am very pleased with this financing package. The equity components are at terms more favorable than the current market price of our stock and are with investors who have a long-term commitment to the Company. In addition, we believe the credit facility amendments will provide the flexibility to fuel further growth and expansion where it makes financial sense in lieu of issuing additional equity."

Mr. Gasparini added, "Operationally, the Company is doing great. We are experiencing very strong growth across the board in all our core testing services. While we are still completing our year-end audit and won't be releasing our 2005 fourth quarter and fiscal year financial results until late February or early March, I can report that after a record Q2 and Q3, our testing volumes increased another 23% in the fourth quarter of 2005 from the third quarter. In addition, we are experiencing very strong growth this month and expect that our testing volumes will increase another 15-20% sequentially from December. Given our current momentum, we anticipate that we will be profitable on a monthly basis by the end of the first quarter, and we believe this will be the final financing package for our current business plan."

A more complete description of the terms of these financings is included with the Company's report on Form 8-K, which was filed with the SEC yesterday.

http://biz.yahoo.com/prnews/060125/nyw078.html?.v=39&printer=1

[cashprofitsss]

NeoGenomics, Inc. Announces 420% Increase in Testing Volumes During the Third Quarter Versus the Same Period in 2004 and the Opening of Three New Testing Lines

FT. MYERS, Fla., Oct. 13 /PRNewswire-FirstCall/ -- NeoGenomics, Inc.
(OTC Bulletin Board: NGNM) announced today that its strong growth continued in
the third quarter with testing volumes up over 65.3% during the quarter versus
the second quarter of 2005 and up over 420% from the third quarter of 2004.
NeoGenomics also announced that during the third quarter, it had begun testing
operations in three new areas: breast cancer, bladder cancer and cervical
cancer.
Robert Gasparini, the Company's President, had the following to say, "Our
growth in testing volumes continued to be very strong during the third
quarter. The 65.3% sequential quarterly growth rate in the third quarter over
the second quarter was a slight increase over the 64.7% increase in testing
volumes we reported for the second quarter over the first quarter. The fact
that we were able to sustain the same sequential growth rate in the third
quarter as in the second quarter, even though we were growing off of a much
larger base of business, is a true testament to the strength of our
operations. Growth was across the board and we picked up several new
customers during the quarter."
Mr. Gasparini went on to say, "I am also pleased to report that we opened
up three new testing lines during the quarter. The tests we are now
performing for breast, bladder and cervical cancer are very complimentary to
our existing businesses. I am particularly pleased with the progress we have
made in marketing these new testing services. We just started offering them
in July, and by September they accounted for approximately 16% of our monthly
testing volume."
NeoGenomics expects to announce its third quarter financial results
shortly.

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/10-13-2005/0004167346&...

[cashprofitsss]

Testing company has 'breakout' quarter

By LAURA LAYDEN, [e-mail]
August 11, 2005 - Naples Daily News

His passion for genetics is in his eyes.

It's in his hands and it's in his smile.

For Robert Gasparini, president and chief scientific officer for Fort Myers-based NeoGenomics Inc., genetics has been a passion for nearly three decades. He has been in the business almost as long as there has been a business, and since he joined NeoGenomics in December the small publicly traded company has seen tremendous growth.

The company's lab has put more focus on genetic testing for cancer. Its customer list is growing by the day and it now does testing for oncologists, pathologists and hospitals across the country.

A year ago, most of the company's clients were in Florida.

In the second quarter, the company landed five new clients outside the state. Company officials describe it as a "breakout" quarter. Revenue increased by 184 percent, compared to the same quarter a year ago.

From the first quarter to the second quarter, gross profits increased 183 percent and testing volumes rose 65 percent.

NeoGenomics still isn't profitable, but that's expected to change by the end of the year, said Steven Jones, a company investor and the acting chief financial officer.

The company reported a loss of $396,531, or 2 cents a share, in the second quarter.

Gasparini is helping to drive the company's growth by making it more competitive in a booming multibillion-dollar industry. NeoGenomics recently added new testing options and new institutional clients that should allow it to triple its case volumes this year.

The company has hired five new people in the last month, including a national sales director.

Jones calls Gasparini a "rare breed of guy" because he knows the industry from the bottom up. He started as a technician with his eye under the microscope and worked his way up to the director of genetics for US Pathology Labs Inc., where he grew annual revenues in his division from zero to $30 million in 30 months.

"I grew up in the business," Gasparini said.

Actually, his interest in genetics was sparked in his junior year at the University of Connecticut, where he received a bachelor's degree in biological sciences. He worked in a genetics lab at the university.

Gasparini spent many years in the academic world.

He was an assistant director for the Prenatal Diagnostic Center at Harvard University and a technical director at Baystate Medical Center, the western campus of Tufts University School of Medicine. Before joining US Pathology Labs, he was the worldwide marketing manager for Ventana Medical Systems, a manufacturer and developer of automated diagnosis procedures based in Tucson, Ariz.

Michael Dent, founder and board chairman for NeoGenomics, said he went out looking for someone with expertise in genetics and found Gasparini. He said the passionate geneticist was just the right person to launch the company's boosters and to help drive "the rocket ride."

"Right now we have more business than we can take," said Dent, who also founded the Naples Women's Center, a thriving obstetrics and gynecology practice. "We are really starting to hit the market and people are recognizing us as a competitor in the marketplace."

The 4-year old company has seen its share of ups and downs. It has taken longer than Dent expected to turn a profit. Once the lab becomes profitable, he said, the focus will turn more toward genetic research, which has always been a part of his dream and the company's business plan.

Dent has worked closely with faculty from Florida Gulf Coast University in Estero. A joint research program is under way that could one day produce new genetic tests. NeoGenomics recently gave FGCU a $15,000 undergraduate scholarship to help pay the tuition for students interested in genetics.

Randall Alberte, FGCU's biotechnology director, said he sees researchers working for the university and NeoGenomics.

"We would be sharing equipment, resources and expertise," he said. "We have every expectation that we will invent things, and some of those will become successful in a commercial environment, or other type of environment. Some of it might be licensed to other entities or developed by spin off companies developed by the university or through other partnerships."

When Dent founded NeoGenomics his primary focus was on pediatric and prenatal testing, dovetailing with his own medial practice. Prenatal testing is used on pregnant women to determine the health of the embryo. Pediatric testing is done on newborns and young children to detect genetic defects.

As science has advanced over the past five years, genetic testing has become more widely used in the diagnosis of cancer and that's driving the new focus at NeoGenomics. The advanced testing can also be used to determine the prognosis for patients with cancer.

"There are good cancers and there are bad cancers," Gasparini said. "Some women with breast cancer may live 25 years. Some may live 14 months."

H. David Greider, chairman of the pathology department at Naples Community Hospital, said he's impressed with NeoGenomics. His department has used the company for genetic testing for more than three years.

"The genetic exam is very important because it helps us make the diagnosis," he said. "It's certainly important in the prognosis of the patients."

He said what sets NeoGenomics apart from its competitors is its fast turnaround time.

"Previously we were waiting 10 days to get our genetic results back," Greider said. "When we started using NeoGenomics it went from 10 days to three days. That was huge for us because the patients and the doctors were very anxious to get their results and this made a big, big difference."

At the NeoGenomics lab off Daniels Parkway, technicians spend hours looking under the microscope to come up with results. They can analyze human chromosomes, cells, individual genes and DNA.

On a recent Wednesday, Greg Larraga, laboratory genetic supervisor, found indications of myelodysplastic syndrome after looking at chromosomes in a bone marrow sample. The syndrome can develop into acute leukemia.

"This is bad," Gasparini said. "This is not good at all and this is what we do every day, every hour."

Down the hall, a few minutes later another technician found signs of leukemia in another sample.

The lab testing market in the United States is about a $35 billion-to-$40 billion-a-year business, said Jones, acting CFO. Genetic testing revenues are estimated at $1.5 billion to $2 billion a year nationwide and its growing by about 25 percent a year, he said.

There are 300 genetic laboratories in the United States and 240 of them are attached to academic institutions. Of the 60 commercial laboratories, only six are owned by publicly traded companies.

NeoGenomics is looking to grow its testing business by acquiring other laboratories across the country. It's also pushing to do more tests per case to increase its revenues. In the second quarter, more than one test was done for 30 percent of its cases.

The company continues to search for new clients.

"The science is exotic. But the business model is simple," Jones said.

NeoGenomics trades on the Over-the-Counter Bulletin Board under the symbol NGNM. Its shares closed down 5 cents on Wednesday at 35 cents.

[cashprofitsss]

Sale of 10,000,000 shares of NeoGenomics

see SB-2 or SB-2A secondary filing


http://www.nasdaq.com/asp/quotes_sec.asp?mode=&kind=&symbol=cogt&symbol=NGNM&symbol=...

[cashprofitsss]

NeoGenomics, Inc. Announces Results for Second Quarter of FY 2005
Friday July 22, 7:00 am ET


FT. MYERS, Fla., July 22 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM - News) today announced its results for the three months ending June 30, 2005. Significant accomplishments during the quarter included the following:

* 184% increase in Q2 FY 2005 revenues vs. Q2 FY2004

* 50% sequential increase in Q2 FY 2005 revenues vs. Q1 FY2005

* Gross profit increased 183% from Q1 FY2005, resulting in a near
doubling of gross profit margins to 43.8%

* 65% increase in testing volume in Q2 FY 2005 vs. Q1 FY 2005

* 30% of cases ordered more than one test per case vs. 24% of cases in Q1
FY2005

* Landed five new clients outside of the state of Florida

* Entered into $5.0 million Standby Equity Distribution Agreement to fund
strategic initiatives

Robert Gasparini, the Company's President, stated, "I am pleased with the progress we made across the board during the second quarter. We began to experience economies of scale during the quarter, which enabled us to perform more tests in the quarter with only modest increases in laboratory staff. Our revenues increased $115,000 from the first quarter and approximately 85% of this increase fell to gross profit. In addition, our customers continue to embrace our advanced cancer testing algorithm that combines our traditional cytogenetics testing services with our newly initiated Fluorescence In-Situ Hybridization (FISH) and Flow Cytometry testing services. This drove a 65% increase in our testing volume versus the first quarter and a an increase in our number of tests per case."

Mr. Gasparini went on to say, "During the second quarter, we also picked up five new customers outside the state of Florida, many during the month of June, which should further mitigate the seasonality we experienced in previous years."

Steve Jones, the Company's acting Principal Financial Officer and a Director, stated, "Our second quarter results included several General and Administrative expenses that were non-recurring in nature in connection with the roll-out of our new information technology platform and our recent financing activities. In addition, during the second quarter we entered into a $5.0 million Standby Equity Distribution Agreement with Cornell Capital Partners, which will allow us to draw down, at our discretion, as much as $750,000 of equity capital during any seven day period. We believe this access to capital should enable us to take advantage of strategic opportunities that may arise in the future."

The attached financial results should be read in conjunction with the Company's full financial statements, included in the Quarterly Report on Form 10-QSB that will be filed with the SEC shortly.

[cashprofitsss]

June 24 audio interview with Robert Gasparini & Steven Jones @ CEOcast.com Free registration.

http://www.ceocast.com/index.cfm

CEOcast has an excellent weekly newsletter.

June 27th newsletter:

http://www.ceocast.com/newsletter_list.cfm?nid=295

[cashprofitsss]

NeoGenomics, Inc. Announces the Appointment of Three New Board Members
Thursday June 23, 7:02 am ET


FORT MYERS, Fla., June 23 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM - News) announced today that pursuant to a written consent of the majority of its shareholders, three new Directors have been added to the Company's Board of Directors. The three new Directors are Dr. Thomas D. Conrad, Mr. George O'Leary and Mr. Peter M. Peterson. The Company also announced that pursuant to the same shareholder action, Dr. Michael T. Dent, Mr. Robert P. Gasparini, and Mr. Steven C. Jones have been reappointed to the Company's Board for another one-year term. The following is a brief background on each of the new Directors.
Dr. Conrad has been involved in starting and operating numerous businesses during his professional career. He is currently the President of Financial Management Corporation, which acts as the General Partner for Competitive Capital Partners, LP, a Naples, Florida-based hedge fund. Prior to his involvement in the fund management business, Dr. Conrad was involved with, among others, The Military Benefit Association and The Government Employees Association, both large life insurance companies. Dr. Conrad has taught at five universities, been a cattleman, an Army pilot and a restaurateur. Before coming to Florida, he was a member of the Reagan Administration as an Assistant Secretary of the United States Air Force. Dr. Conrad has a B.S. and an M.B.A. degree from the University of Maryland and received his Ph.D. in Business from American University.

Mr. O'Leary is currently the Chief Executive Officer of US Medical Consultants, LLC. Prior to assuming his duties with US Medical, he was a consultant to NeoGenomics and acting Chief Operating Officer since October 2004. Prior to becoming a consultant to NeoGenomics, Mr. O'Leary was the President and CFO of Jet Partners, LLC from 2002 to 2004. During that time he grew annual revenues from $12 million to $17.5 million. Prior to Jet Partners, Mr. O'Leary was CEO and President of Communication Resources Incorporated (CRI) from 1996 to 2000. During that time he grew annual revenues from $5 million to $40 million. Prior to CRI, Mr. O'Leary held various positions including VP of Operations for Cablevision Industries from 1987 to 1996. Mr. O'Leary was a CPA with Peat Marwick Mitchell from 1984 to 1987. He received his B.B.A. degree in Accounting from Siena College in Albany, New York.

Mr. Peterson is the founder of Aspen Capital Partners, LLC, which specializes in capital formation, mergers and acquisitions, divestitures, and new business start-ups. Mr. Peterson is also the Chairman and founder of CleanFuel USA and the Chairman and CEO of Innovative Software Technologies (OTC Bulletin Board: INIV - News). Prior to forming Aspen Capital Partners, Mr. Peterson was Managing Director of Investment Banking with H. C. Wainwright & Co. Prior to joining Wainwright, Mr. Peterson was President of First American Holdings and Managing Director of Investment Banking. Prior to First American, he served in various investment banking roles and was the co-founder of ARM Financial Corporation. Mr. Peterson was one of the key individuals responsible for taking ARM Financial public on the OTC market and the American Stock Exchange. Under Mr. Peterson's financial leadership, ARM Financial Corporation was transformed from a diversified holding company into a national clinical laboratory company with more than 14 clinical laboratories and ancillary services with over $100 million in assets. Mr. Peterson also served as President and founder of the Paramount Group, Inc., a privately held real estate company specializing in financing and project consulting. He has also served as an officer or director for a variety of other companies, both public and private. Mr. Peterson earned a Bachelor of Science degree in Business Administration from the University of Florida.

Dr. Michael T. Dent, Chairman of NeoGenomics, had the following to say: "We are delighted to welcome our new Board Members to the Company. Each has a very distinguished background and will help to shape the thinking on our Board in a material way. We are looking forward to working with each, as we take NeoGenomics to the next level."

[cashprofitsss]

NeoGenomics, Inc. Announces Standby Equity Distribution Agreement for Up to $5.0 Million of Equity Financing from Cornell Capital Partners, LP

FORT MYERS, Fla., June 8, 2005 /PRNewswire-FirstCall via COMTEX/ --
NeoGenomics, Inc. (OTC Bulletin Board: NGNM) announced today that it has entered
into a Standby Equity Distribution Agreement ("SEDA") with Cornell Capital
Partners, LP ("Cornell"). Pursuant to the SEDA, the Company may, at its
discretion, periodically sell to Cornell shares of common stock for a total
purchase price of up to $5.0 million. For each share of common stock purchased
under the SEDA, Cornell will pay the Company 98% of the lowest volume weighted
average price ("VWAP") of the Company's common stock as quoted by Bloomberg, LP
on the Over-the-Counter Bulletin Board or other principal market on which the
Company's common stock is traded for the 5 days immediately following the notice
date (the "Purchase Price"). Cornell will also retain 5% of each advance under
the SEDA. Cornell's obligation to purchase shares of the Company's common stock
under the SEDA is subject to certain conditions, including the Company obtaining
an effective registration statement for shares of common stock sold under the
SEDA and is limited to $750,000 per weekly advance. The amount and timing of all
advances under the SEDA are at the discretion of the Company and the Company is
not obligated to issue and sell any securities to Cornell, unless and until it
decides to do so.

Robert Gasparini, the President of NeoGenomics, said, "We are delighted to have
entered into this agreement. Cornell Capital has been a dominant and driving
force in the creation of this innovative financing mechanism. The Company's
primary motivation in securing this equity line was to ensure that the Company
was in a position to move quickly in the event that acquisitions or other
strategic opportunities were presented to the Company. With three of the top ten
genetics laboratories being acquired in the last 12 months, it is clear to our
Board that the industry will consolidate further, and we believe that our
shareholders will realize significant benefits if we are able to participate in
this trend toward consolidation."

Steven Jones, a Director of NeoGenomics and the Company's acting Principal
Financial Officer, said, "Under the terms of the SEDA, equity capital will be
available within five days of each advance request, which is a significant
advantage over raising equity capital through traditional private placements,
which can often take 4-6 months."

Michael Rosselli, a Director with Cornell Capital, stated, "We are very excited
to participate in the genetics and molecular biology testing industry with
NeoGenomics. We have great respect for the NeoGenomics team and we are looking
forward to assisting them in meeting their growth objectives."

SOURCE NeoGenomics, Inc.

CONTACT: Steven Jones, [phone], [e-mail], or Robert Gasparini,[phone], [e-mail], both of NeoGenomics, Inc.

It was evident that by hiring three top level executives that Neogenomics has plans to grow and not be acquired. Instead, with this loan they are going to do the acquiring! I figured that the two partners who left were in it to build it up and sell it off. Jones and Gasparini had other plans. I still think that eventually LabCorp or Quest will end up buying NGNM. They will have to pay a lot more for it then.

[cashwealth]

cash, nice find!!! I like most is 'aquisitions'...future looks bright.

cw

[cashprofitsss]

Added Top Senior Management Persons

Company Interview Excerpt

ROBERT GASPARINI - NEOGENOMICS INC (NGNM)
Full article published: 4/18/2005

TWST: What is NeoGenomics?

Mr. Gasparini: NeoGenomics is a cancer genetics testing laboratory. we are one of six genetics labs in the State of Florida and one of only 300 such labs in the United States. In the genetics testing arena, there are basically three applications of what we call genetics technology: pediatrics or childhood testing, prenatal or fetal testing and cancer testing. NeoGenomics is a cancer genetics testing laboratory.
TWST: How did NeoGenomics begin its existence? What were any of the significant milestones you've been through?
Mr. Gasparini: Dr. Dent had a genuine interest in genetics as a science and a desire to bring state of the art genetics testing to his patients as well as to southwest Florida. I starting working with Dr. Dent and NeoGenomics as a consultant in June of last year and joined the company full time in January of this year. NeoGenomics' original focus was prenatal testing but over the last two and a half years there has been a definite trend, at least from a customer perspective, for cancer testing. Couple this with the bigger picture in that there are only 300 genetic testing laboratories in the US and you can start to see that there has been and will continue to be a real need for this type of testing here in Florida and throughout the US. Currently, there are only six genetic testing laboratories in Florida; three of which are located in academic institutions and pretty much only serve their constituents. That leaves three private genetics labs in Florida to serve a burgeoning population and explains why an awful lot of genetic testing work leaves the state on a daily basis. Although I have only been here for a short while, other significant milestones during my tenure include opening up a FISH laboratory, opening up a Flow Cytometry laboratory, hiring two (very) senior management individuals, Steve Purcell, our CFO, and George O'Leary, our COO, and just recently, re-financing the company's debt and raising a significant amount of additional capital...

http://archive.twst.com/notes/articles/abm609.html

Also looking for VICE PRESIDENT CONTROLLER on careerbuilder.com:

DESCRIPTION
VICE PRESIDENT CONTROLLER - NeoGenomics, Inc., is one of the fastest growing genetics testing companies in the United States. Based in Ft. Myers, NeoGenomics is seeking a Vice President and Controller to develop the financial infrastructure necessary to support and enhance the company's rapid growth. NeoGenomics is a publicly traded company that has recently received new financing and is ready to execute its' aggressive business plan.

The ideal candidate should have the following qualifications:

A CPA with 10+ years of experience with the combination of both public accounting and private company experience. Large accounting firm would be a plus.

Previous experience as a Controller. experience in the healthcare/laboratory environment would be helpful.

Exposure to systems development, acquisitions, financial analysis, credit and collections and public company reporting.

Strong Computer skills.

Should have a "hands on" personality and the desire to build and develop systems and processes.

If you would like to be part of an exciting, growth company, please call Helen Edenfield at 239-768-0600.

http://executive.careerbuilder.com/JobSeeker/Jobs/JobDetails.aspx?ipath=OCT&Job_DID=J3X54C5WL7DV....

must have plans for a good size workforce...

[cashprofitsss]

Here's where the two former MVP partners went:

http://www.detnews.com/2005/business/0501/05/C02-50424.htm

Southfield firm joins the health care field

SOUTHFIELD -- Michigan natives John Elliott and Lawrence Kuhnert want to provide home health care services on a national scale, and they're using a Southfield-based staffing company, Arcadia Services Inc., as the springboard.

Elliott and Kuhnert are merger-and-acquisition specialists who had both owned health care companies. Early last year they led a group of investors in the acquisition of publicly traded Critical Home Care, a New York-based durable medical equipment supplier with annual revenues of $5 million. Elliott is chairman and CEO, and Kuhnert is president.

Last May, they acquired Arcadia Services, which had 2003 revenues of $75 million in 21 states, and Arcadia RX, a mail order pharmacy with revenues of $3 million. They moved the parent company's corporate offices from New York to Southfield and changed its name to Arcadia Resources Inc.

According to Elliott, combining prescription drugs and medical equipment with home health care staffing is a unique approach that should provide a competitive advantage. "Our whole goal is to give people all they need to keep them out of the hospital, assisted living or a nursing home," he said.

Another goal is to make Arcadia a household name in the highly fragmented health care services industry.

Arcadia Services got its start in 1978 under another name as a business staffing company. The nonmedical side of the business has nine offices in southern Michigan and annual revenues of $17 million.

Most of Arcadia's growth should come from providing services to the country's elderly population, which is expected to grow from 35 million to 79 million in 2030. The private-duty home health care market that Arcadia specializes in is projected to grow from $41 billion to $193 billion by then, according to The Remington Report, a magazine covering the home care industry.

Elliott expects existing operations to maintain the recent growth rate of 18 percent a year while he and Kuhnert aggressively pursue acquisitions, particularly in popular retirement states like Florida and Arizona. During 2004 they acquired two staffing and two medical equipment companies in Illinois, North Carolina, Massachusetts and Florida.

All but five of Arcadia's 75 home health care staffing offices are licensed to independent affiliates like Julie Nye of Metrostaff in Lathrup Village, which provides health care staffing for about 120 private clients and several hospitals and nursing homes.

Arcadia handles payroll, billing, collections, employee benefits and quality assurance for Metrostaff. "Being affiliated with Arcadia allows us to concentrate on recruitment, placement and client satisfaction," Nye said.

According to Nye, the new owners have made recruitment and retention easier by beefing up the health and retirement benefits program and opening it up to employees who work less than 30 hours a week. Many health care workers have part-time schedules, and only 4,000 of Arcadia's total work force of 12,000 are working at any one time.

The financial incentives for signing up patients for Arcadia's prescription drug service or medical equipment also will help with employee retention, according to Elliott.

Bringing Arcadia Resources to Michigan is a homecoming of sorts for Elliott, who grew up in Detroit, and Kuhnert, who grew up in Adrian, but they aren't moving back themselves. They both live in Naples, Fla., where they will maintain offices.

Arcadia Resources

http://www.arcadiaresourcesinc.com/html/1_4about.htm

[cashprofitsss]

not a very good PR

...2 of the 3 partners jump ship -from from their MVP partnership and Neogenomics...company going deeper into debt -they already had 1.5 million deal for debt financing from these guys...no PR's about furthering their business into the Eastern US during last couple of months...special deal where Aspen allowed to purchase 2,500,00 shares at .50 in the future...

[sukycospito]

NeoGenomics, Inc. Announces Agreement for up to $1.5 million in Debt Financing from Aspen Select Healthcare, LP
Tuesday March 29, 10:13 am ET


FORT MYERS, Fla.--(BUSINESS WIRE)--March 29, 2005--NeoGenomics, Inc (OTC BB: NGNM - News) announced today that it has entered into an agreement with Aspen Select Healthcare, LP (formerly known as MVP 3, LP or "MVP") which will provide new funding for the Company's business plan and repay existing indebtedness. Under the terms of the agreements, Aspen Select Healthcare, LP ("Aspen"), a Naples, Florida-based private investment fund which is controlled by Steven Jones, a Director of NeoGenomics, Inc., will make available up to $1.5 million of debt financing in the form of a revolving credit facility (the "Credit Facility"). The Credit Facility, which has an initial maturity of March 31, 2007, refinances the Company's existing indebtedness of $740,000 owed to MVP 3, which was due on March 31, 2005, and provides for additional availability of up to another $760,000. Aspen is managed by its General Partner, Medical Venture Partners, LLC.
ADVERTISEMENT


Under the terms of the Credit Facility, the Company will be able to borrow up to 80% of its accounts receivable that are less than 90 days old, 50% of its net property, plant and equipment balance, and up to $500,000 on an unsecured basis currently, and an additional $500,000 on or before April 30, 2005. The interest rate on the Credit Facility is prime plus 600 basis points, payable monthly in arrears. As part of the transaction, the Company has also issued to Aspen a five year Warrant to purchase 2,500,000 shares of its common stock at an exercise price of $0.50/share.

As part of this transaction, NeoGenomics, Dr. Michael Dent (the Chairman of NeoGenomics), Aspen and certain other individual shareholders have amended and restated their shareholders agreement in order to provide that Aspen will have the right to appoint up to three of seven directors of the Company and one mutually acceptable independent director. The Company also announced that Mr. John E. Elliott and Mr. Lawrence R. Kuhnert had tendered their resignations as directors of the Company as part of these transactions. Messrs Elliott and Kuhnert had served as directors appointed by MVP 3 from the initial transaction in April 2003, and are no longer affiliated with MVP 3 or Medical Venture Partners. Aspen intends to appoint two replacement directors within the next 30-60 days.

The Company has also entered into an amended and restated Registration Rights Agreement with Aspen and certain individual shareholders granting Aspen certain demand registration rights and all of the parties piggyback registration rights.

Robert Gasparini, the President of NeoGenomics, said, "We are delighted to have accomplished this recapitalization. We have made tremendous progress over the last three months in extending our business model into the Eastern U.S., and we believe the recapitalization gives us sufficient capital to become cash flow positive, which we expect will happen in the second half of this year."

Steven Jones, Managing Director of Medical Venture Partners and a Director of NeoGenomics, said "NeoGenomics has the right people and the right product line-up in place to begin to substantially increase revenues. Our confidence in Bob Gasparini and his team to execute on the plan was a major factor in our decision to renew and extend the Credit Facility."

The Company also announced today that it plans to file for an automatic fifteen day extension for the submission of its Form 10-KSB. The Company expects that the Form 10-KSB will be filed on or before April 15, 2005. All of the relevant agreements that comprise the above transactions will be filed with the SEC as part of an 8-K filing.

[cashprofitsss]

10K’s due today on calendar FY’s:

Today is the deadline for companies who use the calendar year as their fiscal year to file a 10K report.

The old SEC deadline for a 10K filing was 90 days from the end of the FY but, in an investor-friendly move, the Agency changed the rule to 75 days.

I saw the above post by DewDiligence on the Biotech Values board.
I expected the 10k to be out by now. I see in some prior years Neogenomics filed delay notices and put out the 10k in April-May months.

[sukycospito]

average volume slowly increasing

[sukycospito]

waking up

[sukycospito]

does look that way

[cashprofitsss]

Re: Should be news coming any time now...

By the increase in volume and share price and the numerous bids in the 50's...I'd say it's going to be real good news that's coming.

[cashwealth]

Should be news coming any time now...

cw

[cashwealth]

Everybody holding shares. 1 hr before closing 140 shares moved, probably MM's. Good job, hold tight!!

cw

[cashprofitsss]

10k was filed last year around this time...maybe the stock will get some action when the annual report comes out soon.

[sukycospito]

not much going on

looks like nothing will wake this stock except earnings and possible research partnership announcements, at least until the company grows a bit larger...IMO

[cashprofitsss]

NeoGenomics, Inc. Announces its Entry into the Flow Cytometry Testing Market

FT. MYERS, Fla.--(BUSINESS WIRE)--Feb. 9, 2005--NeoGenomics, Inc. (OTC BB: NGNM) announced today that it has received all regulatory approvals to offer flow cytometry testing services and has formally entered this market. Flow cytometry uses sophisticated laser-based equipment to analyze cell surface markers and is very effective at diagnosing certain types of cancer. Flow testing is also extremely complimentary to the Company's current cytogenetic and fluorescence in-situ hybridization (FISH) testing services and is generally performed on the same samples as these other tests. As a result the Company can now address approximately $1,200 - $1,400 of revenue per case of the oncology related tests performed for any one patient, whereas previously it only addressed approximately $700 per case of this potential revenue.

Bob Gasparini, the Company's President and Chief Scientific Officer, stated the following, "We are very excited about our entry into the flow market. By offering flow cytometry testing in addition to cytogenetics and FISH testing, we now offer a complete package of genetic-testing platforms to oncologists and pathologists. In addition to making it easier to market our services, we expect that the addition of flow cytometry testing will also allow us to increase our average revenue per case to nearly double what it is today."

[cashwealth]

News on Feb.9.'05.

cw

[cashwealth]

No sales mean market waiting for the co give some directions. I will be interesting pretty soon. Hey, we can go either up or down from here. (just a joke)

cw

[sukycospito]

Why was it an interesting day?

[cashwealth]

Waiting for news. I feel it either this week or early next week. We will fly...just don't know wich way. Very interesting day.

cw

[sukycospito]

http://www.stockta.com/cgi-bin/analysis.pl?symb=NGNM&num1=7&cobrand=&mode=stock